Author Archives: Fredricko

National Psoriasis Foundation awards $450,000 in research grants

Posted on by

Public release date: 4-Jun-2013 [ | E-mail | Share ]

Contact: Noe Baker media@psoriasis.org 503-546-8416 National Psoriasis Foundation

PORTLAND, Ore. (June 4, 2013)Six of the top scientists studying psoriasisthe most common autoimmune disease in the country, affecting 7.5 million Americansand psoriatic arthritis, an inflammatory joint and tendon disease affecting up to 30 percent of people with psoriasis, received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for these chronic diseases.

"National Psoriasis Foundation is dedicated to increasing the number of scientists, dollars and projects dedicated to psoriatic diseases," said Randy Beranek, National Psoriasis Foundation president and CEO. "We are the only organization funding these types of promising research projects, each of which will move us faster toward finding a cure, which is our highest priority."

Learn about the NPF research grant program: http://www.psoriasis.org/research.

Theoharis Theoharides, M.D., Ph.D., professor of pharmacology at Tufts University School of Medicine in Boston, received a two-year, $200,000 Translational Research Grant to take laboratory findings and translate them into real-world applications to manage health. Dr. Theoharides will explore how stress contributes to psoriasis and how molecules derived from chamomile might interrupt this psoriasis-stress connection.

Additionally, five researchers each received a one-year, $50,000 Discovery Grant for early-stage research to advance basic understanding of psoriasis and psoriatic arthritis.

###

The National Psoriasis Foundation is the world's largest charitable funder of psoriasis and psoriatic arthritis research worldwide. Learn more about the Foundation research priorities at http://www.psoriasis.org/research.

About the National Psoriasis Foundation

Read more:

National Psoriasis Foundation awards $450,000 in research grants

New Psoriasis Controlâ„¢ Shampoo Combines Salon Luxury with Fast Relief for Psoriasis, Dandruff and Dermatitis of the …

Posted on by

Anaheim, CA (PRWEB) June 04, 2013

TriDerma, a maker of specialized skin care, announced the launch of its new Psoriasis Control Shampoo, a medical strength shampoo that helps provide fast relief for the itchy and scaly scalp that are symptoms of psoriasis, dandruff and dermatitis.

Psoriasis can affect any skin surface and is marked by a build-up of skin cells called scales. Patches of skin affected by psoriasis become itchy, dry, red, and sometimes painful. It is estimated that half of the 7.5 million Americans with psoriasis are affected by scalp psoriasis. It can appear as one or multiple patches on the scalp, affect the entire scalp, and spread beyond the scalp to the forehead, back of the neck, or behind the ears. It can be difficult to treat psoriasis of the scalp because of the difficulty applying topical psoriasis treatments to the affected area.

TriDerma Psoriasis Control Shampoo contains 3% salicylic acid. Salicylic Acid, approved by the FDA as a treatment for psoriasis, gently exfoliates flakes and scales, and helps relieve itching, redness and irritation due to psoriasis and seborrheic dermatitis. Healing botanicals in the companys proprietary AP4 Genuine Virgin Aloe complex are naturally anti-inflammatory and moisturizing to help relieve and prevent flaking and scaling. Specialized itch-fighting ingredients help stop the urge to scratch. Nourishing botanicals, Pro Vitamin B5 and Vitamin E help promote healthy scalp and hair. TriDerma also added a botanical color protectant, so the shampoo is safe for color-treated hair.

TriDerma has over ten years of experience in the psoriasis segment with its Psoriasis Control Skin Healing Cream. Holly Ahearn, Director of Research and Development at TriDerma, says, Psoriasis Control Shampoo was created in response to customer demand for a shampoo that does not smell like medicine, targets psoriasis symptoms, and also makes hair look great. Psoriasis Control Shampoo is an exclusive salon formula. Ms. Ahearn says it is formulated like a luxurious salon treatment, leaving hair soft and manageable, looking beautiful and smelling fresh and clean.

TriDerma Psoriasis Control Shampoo can be ordered online at http://www.triderma.com.

About Triderma

Headquartered in Anaheim, California, TriDerma has provided fast healing without a prescription for 21 years. Founded upon the determination of one woman seeking a natural healing solution, TriDerma now manufactures over 50 products available online and in the First Aid, Skin Care and Baby section of drugstores and supercenters across the U.S. and the world. TriDerma formulas are purpose-driven to help heal specific skin conditions without the use of cortisone, steroids, parabens or other harmful ingredients. Proprietary formulations made in the USA ensure quality and efficacy are never compromised. TriDerma is a women-owned company. For more information and a store locator, go to http://www.Triderma.com. Follow us on Facebook at Facebook.com/TriDerma.

Contact: Angie Echele 636-633-6499

Originally posted here:

New Psoriasis Controlâ„¢ Shampoo Combines Salon Luxury with Fast Relief for Psoriasis, Dandruff and Dermatitis of the ...

Research and Markets: Global Plaque Psoriasis Pipeline Capsule – 2013

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/55snsq/global_plaque) has announced the addition of the "Global Plaque Psoriasis Pipeline Capsule - 2013" report to their offering.

Fore Pharma's latest report Global Plaque Psoriasis Pipeline Capsule - 2013' provides up-to-date information on key Research and Development (R&D) activities in the global plaque psoriasis market. It covers active plaque psoriasis pipeline molecules in clinical trials, preclinical research, and drug discovery.

This report helps executives track competitor pipeline molecules. The pipeline data presented in this report can be used for identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The scope of the report includes information on plaque psoriasis pipeline molecules by clinical trial stages, company, mechanism of action, and country (The US, Germany, France, Italy, Spain, UK, Japan, and Rest of the World). Plaque psoriasis pipeline molecules licensing activities are also covered in this report.

Key Topics Covered

1. Plaque Psoriasis - Disease Overview

2. Plaque Psoriasis Pipeline Overview

3. Plaque Psoriasis Pipeline by Geography

4. Plaque Psoriasis Phase 3 Clinical Trial Pipeline Insights

Continued here:

Research and Markets: Global Plaque Psoriasis Pipeline Capsule - 2013

Arthritis NZ acknowledges thousands of volunteers

Posted on by

It is National Volunteer Week (15 - 22 June), and Arthritis New Zealand Acting Chief Executive Rob Mitchell acknowledges the thousands of volunteers who willingly donate their time to ensure the activities of Arthritis New Zealand continue. "We simply couldnt do what we do in communities across the country without you," he said today.

"Our volunteers help us in so many different ways, such as collecting during our annual appeal, helping with land and water-based exercise classes, driving, volunteering at childrens camps, assisting at seminars, administration tasks in our offices, and so much more. Without them, Arthritis New Zealand would be unable to provide comprehensive support to the 530,000 New Zealanders living with arthritis."

"Arthritis, it could surprise you. But with the support of volunteers we can break down assumptions, and provide the networks that are so needed in our communities," he concluded.

Arthritis is New Zealands leading cause of disability. Arthritis New Zealand is the national organisation focussed on raising awareness of the more than 140 different forms of arthritis, advocating for those with the condition, and providing advice and support.

We rely heavily on the efforts of our volunteers. If you would like to volunteer for us, we would love to hear from you. Phone 0800 663 463 or visit our website: http://www.arthritis.org.nz.

Read more:

Arthritis NZ acknowledges thousands of volunteers

Arthritis Foundation Tai Chi program to begin in July in Roseland

Posted on by

ROSELAND The Arthritis Foundation Tai Chi program will take place at 9 a.m. Wednesday, July 10, at the East Hanover Volunteer Fire Dept. Building, 323 Ridgedale Ave., East Hanover.

The program is open to residents of East Hanover and Roseland. A physicians release is required. All classes are taught by instructors who have undergone a special Arthritis Foundation instructor-training workshop.

The Arthritis Foundation Tai Chi program is designed for people of all ages seeking a joint-safe exercise routine, but particularly those with mild to moderate arthritis. Research shows moderate physical activity helps people with arthritis feel better and relieves pain. Tai Chi may be especially suitable for people with joint problems because its movements are slow and gentle, and the level of exertion can be adjusted to suit each persons physical condition. In addition, the movements in the style of Tai Chi used by the Arthritis Foundation are performed at higher stances, which make it easier and more comfortable to learn.

The benefits of Tai Chi may include reduced pain and stiffness, improved concentration and memory, greater balance, increased flexibility, enhanced muscle strength, along with improved ability to cope with stress and depression.

To register for The Arthritis Foundation Tai Chi Class or for more information, contact the East Hanover Health Department at 973-428-3035.

See the original post:

Arthritis Foundation Tai Chi program to begin in July in Roseland

Many Stop Taking Rheumatoid Arthritis Meds Too Soon: Study

Posted on by

FRIDAY, June 14 (HealthDay News) -- About half of rheumatoid arthritis patients stopped taking their medications within two years after they started them, a new study finds.

Rheumatoid arthritis affects about one in 100 people worldwide and can cause progressive joint destruction, deformity, pain and stiffness. The disease can reduce physical function, quality of life and life expectancy.

The main reason about one-third of patients discontinued their medications was because the drugs lost their effectiveness, the study authors found. Other reasons included safety concerns (20 percent), doctor preference (nearly 28 percent), patient preference (about 18 percent) and access to treatment (9 percent), according to the study results, which were presented Thursday at the annual meeting of the European League Against Rheumatism (EULAR), in Madrid, Spain.

Rheumatoid arthritis "is a progressive disease, which, if left untreated, can significantly and permanently reduce joint function, patient mobility and quality of life," study lead author Dr. Vibeke Strand, a clinical professor at Stanford University School of Medicine, said in an EULAR news release.

"Studies have shown that patients sustain maximum benefit from [rheumatoid arthritis] treatment in the first two years -- yet our data highlight significant discontinuation rates during this time period," Strand said.

The study included more than 6,200 rheumatoid arthritis patients who started treatment by taking either tumor necrosis factor inhibitors (TNFi) or non-TNFi biologics. In the TNFi group, the percentages of patients who continued taking their medications were about 82 percent at six months, 68 percent at 12 months and 52 percent at 24 months. In the non-TNFi group, the percentages for those corresponding time periods were about 81 percent, 63 percent and 46 percent, respectively.

The average time to medication discontinuation was 26.5 months in the TNFi group and 20.5 months in the non-TNFi group, the investigators found.

"While there is no cure for [rheumatoid arthritis], initiating treatment early and improving adherence can enable patients to lead active and productive lives," Strand said in the news release.

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

-- Robert Preidt

Read the original here:

Many Stop Taking Rheumatoid Arthritis Meds Too Soon: Study

Common Childhood Vaccine Won't Worsen Juvenile Arthritis: Study

Posted on by

TUESDAY, June 18 (HealthDay News) -- Measles-mumps-rubella (MMR) booster vaccinations do not appear to worsen disease activity in children with juvenile arthritis, according to a new Dutch study.

"The safety of MMR vaccination has been questioned because disease flares have been described after MMR vaccination," wrote Dr. Marloes Heijstek, of the University Medical Center Utrecht in the Netherlands, and colleagues. "Our trial does not show an effect of vaccination on [juvenile arthritis] activity."

The study included 137 juvenile arthritis patients, aged 4 to 9, who had received primary MMR vaccinations and were randomly assigned either to receive an MMR booster shot or not receive a booster. During follow-up, juvenile arthritis disease activity was about the same for both groups, according to the study, which was published in the June 19 issue of the Journal of the American Medical Association.

The average number of disease flares per patient was 0.44 in the booster shot group and 0.34 in the non-booster group, and both groups had a similar percentage of patients with one or more flares.

Juvenile arthritis is the most common childhood rheumatic disease, and affects between 16 and 150 children per 100,000. Patients with juvenile arthritis are at increased risk for infections due to weakened immune systems caused by the disease or its treatment. Preventing infections in these patients requires safe and effective vaccinations that do not increase disease activity, the researchers noted in a journal news release.

-- Robert Preidt

Copyright 2013 HealthDay. All rights reserved.

SOURCE: Journal of the American Medical Association, news release, June 18, 2013

Read the original:

Common Childhood Vaccine Won't Worsen Juvenile Arthritis: Study

Common Childhood Vaccine Won’t Worsen Juvenile Arthritis: Study

Posted on by

TUESDAY, June 18 (HealthDay News) -- Measles-mumps-rubella (MMR) booster vaccinations do not appear to worsen disease activity in children with juvenile arthritis, according to a new Dutch study.

"The safety of MMR vaccination has been questioned because disease flares have been described after MMR vaccination," wrote Dr. Marloes Heijstek, of the University Medical Center Utrecht in the Netherlands, and colleagues. "Our trial does not show an effect of vaccination on [juvenile arthritis] activity."

The study included 137 juvenile arthritis patients, aged 4 to 9, who had received primary MMR vaccinations and were randomly assigned either to receive an MMR booster shot or not receive a booster. During follow-up, juvenile arthritis disease activity was about the same for both groups, according to the study, which was published in the June 19 issue of the Journal of the American Medical Association.

The average number of disease flares per patient was 0.44 in the booster shot group and 0.34 in the non-booster group, and both groups had a similar percentage of patients with one or more flares.

Juvenile arthritis is the most common childhood rheumatic disease, and affects between 16 and 150 children per 100,000. Patients with juvenile arthritis are at increased risk for infections due to weakened immune systems caused by the disease or its treatment. Preventing infections in these patients requires safe and effective vaccinations that do not increase disease activity, the researchers noted in a journal news release.

-- Robert Preidt

Copyright 2013 HealthDay. All rights reserved.

SOURCE: Journal of the American Medical Association, news release, June 18, 2013

Read the original:

Common Childhood Vaccine Won't Worsen Juvenile Arthritis: Study

Rheumatoid Arthritis Treatment May Not Work As Well for Heavier Patients

Posted on by

TUESDAY, June 18 (HealthDay News) -- Overweight and obese people with rheumatoid arthritis are less likely to go into remission in the early stages of the disease and require much more drug treatment than people with normal weight, according to a new study.

The study included nearly 350 people with early rheumatoid arthritis (RA) who underwent a treatment meant to achieve remission of their disease. The strategy included strict follow-up visits, as well as treatment with steroids and the drug methotrexate, combined with anti-tumor necrosis factor (anti-TNF) therapy if a good response didn't occur. Anti-TNF drugs are used to reduce inflammation in a variety of conditions.

At six and 12 months of follow-up, overweight and obese patients had lower rates of remission. After 12 months, a higher percentage of overweight and obese patients were still on anti-TNF therapy, compared to normal-weight patients.

The researchers also said overweight and obese patients required 2.4 times more anti-TNF therapy throughout the study than normal-weight patients.

The study was presented Friday at the annual meeting of the European League Against Rheumatism in Madrid, Spain. The data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

"Obesity and rheumatoid arthritis are both on the rise, with devastating effects on individuals and society as a whole," study author Elisa Gremese said in an organization news release. "These data reinforce the link between obesity and inflammation, and establish that [weight] is one of the few modifiable variables influencing the major outcomes in RA."

"There is an urgent need to address the issues of overweight and obesity to improve patients' chances of successful remission," said Gremese, of the Institute of Rheumatology and Affine Sciences at the Catholic University of the Sacred Heart, in Rome.

Rheumatoid arthritis affects about one in 100 people worldwide. It can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, quality of life, life expectancy and the ability to work.

-- Robert Preidt

Copyright 2013 HealthDay. All rights reserved.

Visit link:

Rheumatoid Arthritis Treatment May Not Work As Well for Heavier Patients

Patients with early arthritis consume less alcohol than controls, regardless of type of arthritis

Posted on by

Public release date: 19-Jun-2013 [ | E-mail | Share ]

Contact: Kirsty Doole kirsty.doole@oup.com 44-186-535-5439 Oxford University Press

Patients who have early arthritis consume less alcohol than controls, regardless of the type of arthritis, according to a new study published online today in the journal Rheumatology. In rheumatoid arthritis (RA) specifically, the inverse association between alcohol and disease was greater in men than it was in women.

Many new risk factors for RA have been discovered, although the only environmental risk factor that has been consistently shown to be associated with the disease is smoking. Studies examining alcohol consumption and RA have so far had conflicting results. In this new study, Annekoos L. Huidekoper, Diane van der Woude, and colleagues set out to investigate whether there is an association between alcohol consumption and arthritis in general, and with RA in particular.

A total of 992 patients who had had arthritis and different diagnoses including RA, osteoarthritis, reactive arthritis, spondylarthritis, and psoriatic arthritis for two years or less, as well as 5,868 controls, were asked either by a trained research nurse, or through self-administered questionnaires, about their alcohol consumption. Those interviewed by a nurse were asked for an exact number of alcoholic drinks consumed per week, while those who filled in the questionnaire were asked (a) whether they consumed alcohol, and (b) if they did, how many units per week did they consume?

There was a striking inverse relationship between drinking alcohol and the presence of all forms of arthritis. While 83% of the controls reported drinking alcohol, 53-68% of arthritis patients reported consuming alcohol. The lowest figure came from respondents with ACPA-positive RA*, while the highest figure came from patients with psoriatic arthritis. In patients with RA, the inverse association between alcohol and the disease was greater in men than it was in women, although remarkably this difference was not seen in the patients with other types of arthritis. However, the study did not find any significant dose-response relationship, nor did they detect an association between alcohol and the rate of joint destruction when examined over seven years.

Diane van der Woude, one of the lead authors of the study, commented: "Our findings can be interpreted in several ways. One hypothesis might be that alcohol may suppress both the innate and adaptive immune system leading to a decrease of joint inflammation, as has been suggested by some previous studies.

"Another possible explanation for our findings is that people with arthritis drink less alcohol due to their illness. This explanation seems probable since we observed a relationship between alcohol and the level of inflammation."

Dr van der Woude also said: "The observed differences between men and women can also be interpreted in different ways. Perhaps men are more susceptible to the influence of alcohol on the pathophysiology of RA, or the decrease in alcohol consumption caused by the decrease in general well-being is more evident among individuals who consume more alcohol to begin with (often men) and who develop the most severe disease."

While the study does have limitations, such as the risk of interviewer bias and recall bias, it is, to the authors' knowledge, the first to include not just patients with RA, but also patients with other types of arthritis, and the finding that alcohol is also inversely associated with these other types of the disease sheds new light on the association between alcohol consumption and RA. It also questions whether the effect of alcohol on the underlying pathophysiology is specific to RA.

Read more:

Patients with early arthritis consume less alcohol than controls, regardless of type of arthritis